Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (1349)	5/4/1998 10:23:00 PM
From: walkers	Read Replies (1) \| Respond to of 2173

Thanks for all your input about the stock. Here's my 2 cents. I am a Type 1 Diabetic. Because of the way our bodies work, this could be a blockbuster drug. Glucose enters the blood stream 2 ways: through the food we eat and from our livers. In a person whose pancreas is working correctly, two hormones are secreted. One, amylin, tells the liver to stop secreting sugar when we eat. But, in many diabetics, the pancreas is not producing amylin and, consequently, the liver just keeps pumping out glucose even while the person is eating -- consuming even more glucose through food. This problem results in high blood sugars after meals. This is an extremely important problem. If the amylin being developed and tested now works the same way as the amylin made by a healthy pancreas, it will be a fantastic breakthrough. May's issue of Diabetes forecast has a 3 page story on amylin. It does not mention the company, but that was easy to find on the Internet. The most interesting thing about the article is the fact that some of the people undergoing testing were type 2 diabetics. That means it is helpful not only to type 1's who are not manufacturing amylin, but to type 2's, as well. Type 2's may have an impaired ability to manufacture enough whereas type 1's are not manufacturing any. The market for a drug which would help both type 1's and type 2's is mind boggling. Remember, Rezulin -- the Warner Lambert drug -- is primarily aimed at type 2's. Amylin sounds like it would be aimed at both types. Good luck to us all. My husband and I agree that there must be a major news announcement in the offing. And, given today's volume, we can expect that it will be soon. Maxine & Steve